FY2024 EPS Estimates for Immunic Lowered by Analyst

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at Brookline Capital Management dropped their FY2024 earnings estimates for shares of Immunic in a research note issued on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian now anticipates that the company will earn ($0.89) per share for the year, down from their prior forecast of ($0.87). The consensus estimate for Immunic's current full-year earnings is ($0.92) per share. Brookline Capital Management also issued estimates for Immunic's Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.03) EPS.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same period in the previous year, the company earned ($0.54) earnings per share.

Several other research analysts also recently commented on the stock. StockNews.com raised shares of Immunic from a "sell" rating to a "hold" rating in a research note on Tuesday, August 13th. Piper Sandler reiterated an "overweight" rating and issued a $28.00 price target on shares of Immunic in a report on Tuesday, July 16th. Leerink Partnrs raised Immunic to a "strong-buy" rating in a research report on Monday, September 9th. B. Riley started coverage on Immunic in a research report on Tuesday, August 27th. They set a "buy" rating and a $6.00 price target on the stock. Finally, Leerink Partners restated an "outperform" rating and issued a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Immunic currently has a consensus rating of "Buy" and an average target price of $11.20.

Immunic Price Performance

IMUX stock remained flat at $1.59 during midday trading on Friday. The company's stock had a trading volume of 163,014 shares, compared to its average volume of 537,238. Immunic has a twelve month low of $0.95 and a twelve month high of $2.11. The stock has a market cap of $143.23 million, a price-to-earnings ratio of -0.87 and a beta of 1.84. The company's 50-day moving average price is $1.51 and its two-hundred day moving average price is $1.35.

Hedge Funds Weigh In On Immunic

A number of large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Immunic in the 1st quarter worth approximately $25,000. Ikarian Capital LLC grew its holdings in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Immunic during the first quarter worth $9,266,000. BVF Inc. IL purchased a new stake in shares of Immunic during the 1st quarter valued at $11,752,000. Finally, Vanguard Group Inc. boosted its position in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.